All In Biotech

Drug Trial Radar · NCT00971165

Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension

A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study

Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 655 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

655

Actual

Start

Jul 2010

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Financiadora de Estudos e Projetos
First posted
Sep 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

High blood pressure is the major risk factor for Cardiovascular disease (CVD). The prevalence of hypertension in Brazil was established in population-based studies conducted in different cities and States, varying from 22.3 to 44% of adults. The benefit of drug treatment of hypertension to prevent major cardiovascular events was consistently demonstrated in a large series of clinical trials controlled by placebo. Diuretics are at least as efficacious as other blood pressure-lowering drugs, are well tolerated, have longer duration of action and the advantage of very low cost to be used in a population intervention. Chlorthalidone is the more efficacious agent. Its main limitation is to induce hypokalemia in a proportion of patients, an adverse effect that can be antagonized by a potassium-sparing diuretic, as amiloride. A study comparing diuretic with an ARB agent is therefore recommendable in Brazil, in order to support the decisions of the Health Secretary in regard to blood pressure agents supply for the Brazilian population. Such a study was demanded and funded by the Health and Technology Ministries in Brazil.

Conditions

  • Hypertension
  • Cardiovascular Disease

Interventions

  • losartanDrug

    Oral losartan up to 100 mg daily fo 18 months

  • Chlorthalidone plus amilorideDrug

    Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood pressure variation and proportion of use of add-on drugsTime frame: 18 months
  2. Adverse eventsTime frame: 18 months
  3. Development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG.Time frame: 18 monyhs

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de Clínicas de Porto Alegre, UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.